Annexon Biosciences

📍 South San Francisco, United States🗓 Founded 2011👥 82 employees💰 Last funded Jun 2020
Biotechnology Research🌐 annexonbio.com
Website LinkedIn
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2011
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Annexon Biosciences?
Annexon Biosciences has 2 investors on record on gritt.io and 2 late-stage investors.
When did Annexon Biosciences last raise funding?
The most recent investment in Annexon Biosciences recorded on gritt.io was in June 2020.
When was Annexon Biosciences founded?
Annexon Biosciences was founded in 2011.
What industry is Annexon Biosciences in?
Annexon Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Annexon Biosciences based?
Annexon Biosciences is headquartered in South San Francisco, United States.